

## Notice to Physicians

### NEW FEE

The province of Nova Scotia has received a prophylactic COVID-19 therapy for high-risk patients.

A new health service code is being developed for the intramuscular injection of tixagevimab and cilgavimab (Evusheld) for use as pre-exposure prophylaxis in individuals with severe immunocompromise, with no known history of cardiovascular disease. Prescribed by primary care providers or specialists and submitted to the [COVID-19 Non-Severe Therapy Pharmacist Consult Service](#) for criteria confirmation and facilitation of supply distribution for administration by the prescriber or their delegate.

This will be effective July 1, 2022; however, physicians are asked to hold their claims until the system is updated on July 22, 2022. Notification will be published in the July bulletin when claims can be submitted.

Category	Code	Description	Base Units
ADON	13.59R	<b>Evusheld injection for the prevention of COVID-19 in immune compromised adults and children</b>  <b>Description</b> Evusheld Intramuscular Injection for the prevention of COVID-19 in severely immune compromised adults and children.  <b>Billing Guidelines:</b> Payable at 6 MSU for the first injection and 3 MSU for subsequent injections May be claimed in addition to a visit Eligible for 13.59M tray fee where appropriate  <b>Multiples:</b> 2 IM injections	6 MSU +MU

Community-based family physicians are reminded that in order to claim for simple injections or immunizations provided by a nurse, the physician must directly employ the nurse and be physically on the premises. If the nurse is not employed by the physician, such as instances in which the nurse is an employee of the NSHA or IWK, no services rendered by the nurse may be claimed by the physician.

Physicians are also reminded they may not claim for injections, immunizations or other services provided by pharmacists.